Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MCOLN3 | Q8TDD5 | 2/20 | 0.43 |
| ▸ | CRHBP | P24387 | 1/20 | 0.43 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3008572 | 1.00 | MEN1 (0.49) | MEN1KMT2AL3MBTL1SMN1; SMN2LMNA | |
| SCHEMBL2820255 | 0.85 | MEN1 (0.53) | MEN1KMT2AL3MBTL1SMN1; SMN2LMNA | |
| SCHEMBL6648839 | 0.79 | KMT2A (0.46) | MEN1KMT2AL3MBTL1SMN1; SMN2LMNA | |
| SCHEMBL6648841 | 0.79 | KMT2A (0.46) | MEN1KMT2AL3MBTL1SMN1; SMN2LMNA | |
| SCHEMBL18230449 | 0.77 | KMT2A (0.69) | MEN1KMT2ALMNAPOLBALDH1A1 | |
| SCHEMBL18230447 | 0.77 | KMT2A (0.69) | MEN1KMT2ALMNAPOLBALDH1A1 | |
| SCHEMBL29451625 | 0.74 | ALDH1A1 (0.49) | KMT2AL3MBTL1SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL8512706 | 0.72 | TNF (0.54) | SMN1; SMN2LMNAPOLBALDH1A1MAPT | |
| SCHEMBL29451375 | 0.72 | ALDH1A1 (0.53) | MEN1KMT2AL3MBTL1SMN1; SMN2LMNA | |
| SCHEMBL11964594 | 0.70 | VCAM1 (0.41) | MEN1KMT2ASMN1; SMN2ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8242118-B2 | Arylsulfonamide derivatives for use as CCR3 antagonists in the treatment of inflammatory and immunological disorders | AXIKIN PHARMACEUTICALS INC. (US) | 2012-08-14 | — | — | US | disclosed |
| US-20100204213-A1 | ARYLSULFONAMIDE DERIVATIVES FOR USE AS CCR3 ANTAGONISTS IN THE TREATMENT OF INFLAMMATORY AND IMMUNOLOGICAL DISORDERS | BAYER HEALTHCARE AG (DE) | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204213-A1 | ARYLSULFONAMIDE DERIVATIVES FOR USE AS CCR3 ANTAGONISTS IN THE TREATMENT OF INFLAMMATORY AND IMMUNOLOGICAL DISORDERS | CCR3, CCR1, CCR2 | MEN1 4873/4885KMT2A 2753/4885L3MBTL1 4577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.